Preliminary Anticonvulsant and Toxicity Screening of Substituted Benzylidenehydrazinyl-N-(6-substituted benzo[d]thiazol-2-yl)propanamides

Table 3

Phase II quantitative anticonvulsant evaluation of selected active compounds.

Compound				PI^c
	MES	scPTZ		MES	ScPTZ
5h	27.9 ± 1.43^d	188.6 ± 9.23	378.5 ± 17.09	13.5	2.0
5p	28.4 ± 0.88	89.1 ± 7.72	287.1 ± 22.13	10.1	3.2
PHY	9.5 ± 0.77	>300	65.5 ± 12.06	6.9	<0.22
CBZ	15.8 ± 1.02	>100	71.6 ± 12.07	8.1	<0.22

Number of animals used = 08; solvent used: polyethylene glycol (0.1 mL, i.p.), ED₅₀—median effective dose eliciting anticonvulsant protection in 50% animals.
^bTD₅₀ median toxic dose eliciting minimal neurological toxicity in 50% animals.
^cPI = protective index (TD₅₀/ED₅₀). ^dData in parentheses are the 95% confidence limits.